Medical Imaging Emerges in Clinical Trials: A 2007 Assessment
CenterWatch 2007
The FDA, in an effort to increase new drug approvals, has identified imaging as an important technology for assessing new therapeutics and accelerating drug development in the future.
EventsWe invite you to visit PAREXEL at these upcoming industry events. Events are a great way to get to know our experts, discuss your outsourcing challenges, and learn how PAREXEL’s global reach, technology and expertise can help your organization.
| Suggest an eNewsletter Topic |
Barbara Tardiff, M.D., M.B.A
Barbara E. Tardiff, M.D., M.B.A., Corporate Vice President, Data Sciences
PAREXEL International
Dr. Tardiff joined PAREXEL in 2007 with a unique background in medicine, information management, business administration, clinical research, and science. She is an expert in the integration, deployment, and evaluation of biomedical data, and has participated in a broad range of scientific and operational development activities. Dr. Tardiff has held executive positions in the pharmaceutical industry overseeing biomedical and clinical information systems, and is Board certified in pediatrics and anesthesiology.
As Corporate Vice President for Data Sciences for PAREXEL, Dr. Tardiff is responsible for the company’s worldwide data services, including data management, biostatistics, programming, and information technology strategy and implementation. “Data management in the bio/pharmaceutical industry has evolved from a transaction-based function to a strategic function that is essential for successful clinical research and drug development,” Dr. Tardiff said. “I want to help PAREXEL’s clients take full advantage of the benefits of the latest generation of eClinical technologies so they can accelerate their development projects and compete more effectively in a challenging economic climate. Part of that effort is ensuring that our technology resources are optimized so we are in the prime position to meet our clients’ information management requirements.”
Before joining PAREXEL, Dr. Tardiff was Executive Director, Clinical and Regulatory Information Services, for Merck & Co., where she was responsible for strategy, implementation, delivery, and support of information technology, products, and services for Merck Research Laboratories’ clinical development and regulatory teams. Prior to that, she was Vice President of Informatics, Data Management, and Biostatistics at Regeneron Pharmaceuticals. Dr. Tardiff also served as Vice President, Biomedical Informatics, for iBiomatics, a subsidiary of SAS Institute, and was the Director of Clinical Data Integration at the Duke Clinical Research Institute (DCRI). She remains a member of the DCRI faculty and an Assistant Consulting Professor at Duke University.
Dr. Tardiff holds a B.S. degree in biochemistry and biophysics from Oregon State University. She received her medical degree from Yale University, where she also earned M.S. and M.Phil. degrees. Dr. Tardiff received her M.B.A. from Duke University’s Fuqua School of Business. She has made more than three dozen invited presentations at major industry meetings on a broad range of clinical and data management topics, as well as authoring numerous published research articles and book chapters. Dr. Tardiff is also active in the effort to establish pharmaceutical industry data standards through the Clinical Data Interchange Standards Consortium (CDISC) and Health Level Seven (HL7).